Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (451-460 of 713) with videos related to

Pageof 72
Sort By:
British Journal of Haematology|March 28, 2013
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDKoichi Takahashi, Hagop Kantarjian, Naveen Pemmaraju, et al.
Haematologica|June 20, 2015
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosisNaval Daver, Jorge Cortes, Kate Newberry, et al.
Blood|November 8, 2003
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignanciesJean-Pierre J Issa, Guillermo Garcia-Manero, Francis J Giles, et al.
Cancer|July 12, 2008
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemHagop Kantarjian, Susan O'Brien, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2009
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndromeWanlong Ma, Hagop Kantarjian, Benjamin Bekele, et al.
Blood|July 30, 2010
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaHagop Kantarjian, Farhad Ravandi, Susan O'Brien, et al.
Haematologica|September 16, 2017
Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanismsPeter P Ruvolo, Huaxian Ma, Vivian R Ruvolo, et al.
Blood|April 9, 2004
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemiaHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
American Journal of Hematology|January 17, 2020
A heavy metal baseline score predicts outcome in acute myeloid leukemiaMaro Ohanian, Philippe Telouk, Steven Kornblau, et al.
Journal of the American Heart Association|July 26, 2024
Cardiovascular Diseases Increase Cancer Mortality in Adults: NHANES-Continuous StudyOmar M Makram, Tochukwu Okwuosa, Daniel Addison, et al.
Pageof 72

Showing results (451-460 of 713) with videos related to

Sort By:
Pageof 72
British Journal of Haematology|March 28, 2013
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDKoichi Takahashi, Hagop Kantarjian, Naveen Pemmaraju, et al.
Haematologica|June 20, 2015
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosisNaval Daver, Jorge Cortes, Kate Newberry, et al.
Blood|November 8, 2003
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignanciesJean-Pierre J Issa, Guillermo Garcia-Manero, Francis J Giles, et al.
Cancer|July 12, 2008
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemHagop Kantarjian, Susan O'Brien, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2009
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndromeWanlong Ma, Hagop Kantarjian, Benjamin Bekele, et al.
Blood|July 30, 2010
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaHagop Kantarjian, Farhad Ravandi, Susan O'Brien, et al.
Haematologica|September 16, 2017
Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanismsPeter P Ruvolo, Huaxian Ma, Vivian R Ruvolo, et al.
Blood|April 9, 2004
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemiaHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
American Journal of Hematology|January 17, 2020
A heavy metal baseline score predicts outcome in acute myeloid leukemiaMaro Ohanian, Philippe Telouk, Steven Kornblau, et al.
Journal of the American Heart Association|July 26, 2024
Cardiovascular Diseases Increase Cancer Mortality in Adults: NHANES-Continuous StudyOmar M Makram, Tochukwu Okwuosa, Daniel Addison, et al.
Pageof 72